ImmuCell Corporation ICCC PHARMA

Q: What is the current share price of ImmuCell Corporation (ICCC)?

As of 2026-09-19 21:16 PDT, ImmuCell Corporation (ICCC) trades at $9.84 on NasdaqCM. Its 52-week range is $4.56 to $11.72.

Q: What is the market capitalisation of ICCC?

ImmuCell Corporation (ICCC) has a market capitalisation of $89.37M on NasdaqCM.

Q: What is the P/E ratio of ICCC?

ICCC trades at a trailing price-to-earnings (P/E) ratio of 140.57. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.88.

Q: What is the return on equity (ROE) of ICCC?

ICCC has a return on equity (ROE) of 2.57%. Its return on capital employed (ROCE) is 4.28%.

Q: Is ICCC a good stock to buy?

This page provides a data-driven analysis of ImmuCell Corporation (ICCC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://immucell.com

Company Profile ↓

$9.84

+50.69% 1Y

Mkt Cap$89.37M

P/E140.57

P/B2.88

52W High$11.72

52W Low$4.56

Book Value$3.46

EPS (TTM)$0.07

Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 12.0% CAGR over the past five years.

Healthy Margins

Operating margin of 26.9% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.40.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $27.64M (+4.3% YoY); net profit $-1.04M.
Trailing 12 Months Year-on-year growth — revenue +11.5%, earnings +259.9%.
5-Year Trend Long-term compounding — revenue CAGR 12.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	12.01%
1 Year:	11.50%

Compounded Profit Growth

5 Years:	-
1 Year:	259.90%

Stock Price Performance

1 Year:	+50.69%
6 Months:	+51.85%
3 Months:	+1.44%
1 Month:	-10.55%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 74% of range

$4.56 $11.72

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)39.90 · Neutral

Price Performance

1M-10.55%

3M+1.44%

6M+51.85%

1Y+50.69%

Valuation vs Sector

P/E of 140.57 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 12.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 140.6.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

140.57

Industry PE

24.83

Forward P/E

-89.45

PEG Ratio

Book Value

$3.46

Price to Book

2.88

P/S

2.95

EV/EBITDA

13.36

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

12.01%

Profit 5Y

Revenue (YoY)

11.50%

Earnings (YoY)

259.90%

Profitability & Returns

ROCE

4.28%

ROE

2.57%

ROA

6.25%

Profit Margin

2.57%

Op Margin

26.93%

Gross Margin

40.32%

EPS (Latest Qtr)

$0.21

EPS (TTM)

$0.07

Balance Sheet & Liquidity

Debt/Equity

0.40

Quick Ratio

2.65

Current Ratio

4.75

Debt

$12.45M

Total Assets

$44.11M

Current Assets

Working Capital

Ownership

Promoter Holding

32.00%

Chg in Prom Hold

-0.13%

FII / Inst Holding

20.44%

Chg in FII Hold

0.14%

Financial Snapshot

Enterprise Value

$89.37M

Total Revenue (TTM)

$30.68M

EBITDA

$7.05M

Free Cash Flow

$3.08M

Operating Cash Flow

$5.89M

Shares Outstanding

9.08M

Gross Margin

40.32%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ICCC ImmuCell Corporation PHARMA	9.84	140.57	$89.37M	0.00%	4.28%	2.57%	12.01%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	3.54M	1.75M	-	2.88M	3.01M	-	-	-	-	-	-	-	-	-	5.15M	-	-	4.80M	-	-	5.40M	-	-	6.01M	8.07M	-	5.51M	10.36M
Gross Profit	1.15M	878.52K	1.08M	1.34M	1.85M	1.13M	1.61M	1.66M	1.76M	1.24M	1.20M	1.22M	2.15M	921.35K	935.85K	1.36M	1.49M	950.97K	2.20M	1.25M	1.45M	2.24M	1.28M	1.72M	1.60M	2.07M	2.42M	3.10M	1.71M	1.85M	300.77K	1.04M	1.27M	2.30M	1.23M	1.58M	3.35M	2.82M	2.36M	4.66M
Operating Income	12.56K	-458.67K	40.85K	198.86K	820.05K	213.98K	626.85K	461.44K	698.96K	21.46K	50.47K	119.31K	918.21K	-265.31K	-482.41K	-178.16K	-193.41K	-149.14K	265.30K	-546.93K	-429.82K	196.88K	-691.27K	-251.60K	-374.62K	215.51K	271.09K	570.61K	-619.01K	-616.79K	-2.26M	-1.30M	-1.18M	-300.05K	-1.39M	-574.89K	1.12M	569.56K	20.07K	1.97M
Net Income	-13.34K	-294.78K	10.33K	130.63K	479.08K	94.06K	351.29K	288.81K	452.45K	-9.15K	34.87K	30.29K	584.24K	-218.39K	-339.35K	-221.12K	-798.36K	-249.96K	144.56K	-627.16K	-502.54K	-122.27K	-765.79K	-322.89K	-441.30K	141.11K	147.76K	513.29K	-684.15K	-655.08K	-2.32M	-1.38M	-940.00K	-437.87K	-1.53M	-701.69K	1.45M	501.88K	-139.75K	1.94M
Diluted EPS	0.00	-0.10	0.00	0.04	0.15	0.03	0.11	0.09	0.11	0.00	0.01	0.01	0.12	-0.05	-0.07	-0.04	-0.15	-0.05	0.03	-0.09	-0.07	-0.02	-0.11	-0.04	-0.06	0.02	0.02	0.07	-0.09	-0.08	-0.30	-0.18	-0.12	-0.06	-0.20	-0.09	0.16	0.06	-0.02	0.21
R&D Expense	594.21K	760.67K	361.23K	462.96K	330.67K	271.76K	301.75K	331.14K	302.44K	380.43K	307.72K	253.74K	339.62K	387.01K	585.83K	582.93K	761.89K	908.79K	910.37K	820.05K	984.73K	974.43K	1.09M	1.12M	1.03M	1.00M	1.05M	1.04M	1.14M	1.27M	1.11M	1.10M	1.12M	1.26M	1.03M	786.14K	756.85K	831.86K	694.31K	317.69K

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	4.51M	4.39M	5.11M	5.39M	6.01M	7.60M	10.23M	9.54M	10.43M	10.99M	13.72M	15.34M	19.24M	18.57M	17.47M	26.49M	27.64M
Gross Profit	2.40M	2.30M	2.81M	3.05M	3.06M	4.45M	6.25M	5.42M	5.22M	5.19M	6.74M	6.86M	8.66M	7.65M	3.87M	7.94M	11.45M
Operating Income	-529.91K	-690.28K	-632.73K	245.00K	-19.55K	-206.40K	2.12M	890.20K	-242.84K	-1.45M	-953.91K	-1.38M	257.38K	-2.30M	-5.75M	-1.64M	1.65M
Net Income	-216.49K	-384.68K	-409.51K	89.51K	117.39K	-167.16K	1.21M	508.45K	-168.15K	-2.32M	-1.30M	-1.02M	-78.29K	-2.49M	-5.77M	-2.16M	-1.04M
Diluted EPS	-0.07	-0.13	-0.14	0.03	0.04	-0.06	0.38	0.12	-0.03	-0.42	-0.19	-0.14	-0.01	-0.32	-0.75	-0.26	-0.12
R&D Expense	1.64M	1.49M	1.72M	917.60K	1.15M	2.18M	1.24M	1.24M	2.05M	3.52M	3.69M	4.35M	4.17M	4.49M	4.39M	3.90M	3.04M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	10.75M	10.99M	11.03M	10.96M	11.05M	14.54M	24.70M	34.30M	32.73M	38.69M	40.35M	44.47M	44.86M	43.81M	45.10M	42.53M
Total Equity	9.64M	9.62M	9.28M	9.02M	9.19M	9.40M	9.26M	10.61M	19.72M	23.59M	21.74M	28.99M	28.27M	32.58M	30.38M	24.99M	27.52M	27.06M
Cash & Equivalents	1.20M	975.49K	1.40M	781.52K	2.67M	2.27M	850.03K	1.57M	5.15M	3.80M	2.52M	6.29M	6.95M	10.19M	5.79M	978.74K	3.76M	3.81M
Long Term Debt	-	-	-	1.34M	1.17M	929.23K	-	-	-	8.96M	9.27M	8.42M	9.50M	812.21K	10.23M	-	9.04M	7.49M
Total Liabilities	-	-	1.47M	1.97M	1.84M	1.56M	1.79M	3.93M	4.98M	10.70M	10.99M	9.70M	12.08M	11.89M	14.48M	18.82M	17.58M	15.48M
Current Liabilities	-	-	525.02K	635.00K	665.77K	635.62K	1.01M	792.95K	2.06M	2.06M	2.57M	2.50M	2.21M	2.53M	3.07M	4.20M	4.41M	3.98M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-109.67K	-808.61K	-37.31K	344.39K	1.10M	302.36K	2.90M	-222.31K	1.18M	-373.40K	233.51K	1.32M	954.17K	-1.54M	-4.67M	357.90K	2.48M
Investing Cash Flow	-215.44K	266.45K	-1.19M	1.66M	-1.34M	-1.54M	-4.62M	-4.52M	-12.27M	-1.79M	-3.40M	-2.57M	-1.60M	-3.96M	-1.89M	-461.23K	-1.21M
Financing Cash Flow	100.67K	965.65K	614.58K	-114.79K	-159.30K	-187.16K	2.44M	8.32M	9.75M	889.62K	6.94M	1.91M	3.88M	1.11M	1.75M	2.88M	-1.21M
Capital Expenditure	-459.55K	-116.55K	-243.74K	-275.39K	-597.70K	-1.54M	-2.72M	-3.59M	-17.76M	-2.03M	-1.39M	-4.07M	-2.61M	-3.98M	-1.89M	-465.73K	-1.25M
Free Cash Flow	-569.21K	-925.16K	-281.05K	69.00K	500.96K	-1.23M	181.05K	-3.81M	-16.58M	-2.40M	-1.16M	-2.76M	-1.65M	-5.52M	-6.57M	-107.82K	1.22M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	53.2%	52.5%	55.1%	56.7%	50.9%	58.6%	61.1%	56.8%	50.1%	47.3%	49.1%	44.7%	45.0%	41.2%	22.1%	30.0%	41.4%
Operating Margin %	-11.8%	-15.7%	-12.4%	4.5%	-0.3%	-2.7%	20.7%	9.3%	-2.3%	-13.2%	-7.0%	-9.0%	1.3%	-12.4%	-32.9%	-6.2%	6.0%
Net Margin %	-4.8%	-8.8%	-8.0%	1.7%	2.0%	-2.2%	11.9%	5.3%	-1.6%	-21.1%	-9.4%	-6.7%	-0.4%	-13.4%	-33.1%	-8.1%	-3.8%
ROE %	-2.2%	-4.1%	-4.5%	1.0%	1.2%	-1.8%	11.4%	2.6%	-0.7%	-10.7%	-4.5%	-3.6%	-0.2%	-8.2%	-23.1%	-7.8%	-3.8%
ROCE %	-	-6.8%	-6.1%	2.4%	-0.2%	-2.1%	15.4%	3.9%	-0.8%	-4.8%	-2.6%	-3.6%	0.6%	-5.5%	-14.5%	-4.0%	4.3%

Shareholding Pattern

Insiders

32.00%

Institutions

20.44%

Public Float

30.06%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard Capital Management LLC	2.95%	268.13K	$2.67M
2	Morgan Stanley	2.58%	233.91K	$2.33M
3	Renaissance Technologies, LLC	1.88%	171.09K	$1.70M
4	Cresset Asset Management, LLC	1.49%	135.27K	$1.35M
5	Geode Capital Management, LLC	0.80%	72.27K	$719.09K
6	Dimensional Fund Advisors LP	0.64%	58.45K	$581.60K
7	Bleichroeder LP	0.55%	50.00K	$497.50K
8	Steadtrust LLC	0.50%	45.37K	$451.43K
9	Mesirow Financial Investment Management, Inc.	0.47%	42.48K	$422.69K
10	Citadel Advisors Llc	0.45%	40.50K	$403.00K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ICCC

Google News Sun, 06 Sep 2026

Discipline and Rules-Based Execution in ICCC Response - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOUVBDcm5ZdmdYQzVvbkZ4VWRRWU5oUW45MHBGYngwXzdoRlVvdWlzbHNDZjA3aHRiYnFJcm5fRzN1UWtzb0s2ZjZWLXpmamh0d3BlcVlyZUdVTGVRWDZ1SzQ1T29ScHhzdGNzYUZOblZSTXRsVlktbzdNdXpLbFEwcGQ5bi1Vc040MHdacE…

Google News hu, 13 Aug 2026

ImmuCell Plans About $4.5M Expansion for Calf Health Products - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQQWJ4eDQ0NzBXWGlVUzlCdVZuZU9EOTI4djFGeG5xQ0l3eDhUdWxKUlAtVEtxOWtqbXU0MG5zaWFKNjM0Ri00NlpST25wZEVzNThyM2c0cko4STY0anJ4TkljQkNtcHhkSGpPRk9NVUdENmtzZk1oOVZHMGMtLU9hMFJVYWJacjZBUUhVc3…

Google News Mon, 24 Aug 2026

ICCC | Immucell Corp Financials - Revenue Breakdown - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5vUzZrVnBQQzBPVFNGRVRfV0JYNFFXcFBZOFhOZ0F0aTdBZjJ0XzBxTU5Zc0FSdGJqSjhLNGhqaFYxOVdtSGQ1VXRZd3ZnMnJIM1JvMkJnTEZBSlN4dTNjaUk1Wm5uZWxYNUNMb3VSRGs5bnN3anRr?oc=5" target="_blank">ICCC | …

Google News hu, 27 Aug 2026

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOUEQwSW1jN0Z1b0d6VVJwclk5LVpwdklUZXNsbkxvb1Ryck0xTnpYVk9PRlhxMkxTV0VCSDJPNmJiSGlXSkN5d2tjVHI2eHpIbkZ5cmxSRUZDblI3SGZyMWFUSE5qZGZDQ2U1TUNEbnZVNTNUNDdqWmUtRXphb2E5bGgtUjB5NU5OVW1HZW…

Google News Fri, 24 Jul 2026

ImmuCell: First Defense With Better Execution (NASDAQ:ICCC) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNeVZBci00eE1uNE14Zlh6dnR4dl80bGdZNGdzVGRFM3FodC1WSXA2YWlmRFBqTVJfM19qWnNHUk5md01paTVLbkZUZ1lfNUd6dnJVWDZXRndvTWF6TDRBc0hKNlNuOFNaMk4zcERheG9fbGVrN0EwTEl3cTRBaXFCcERpR3hfNmFYVF9IVT…

Google News Fri, 21 Aug 2026

ImmuCell (ICCC) Shares: Moves 0.40% Lower to $10.05 in the Latest Reading; Price Levels: the $9.55 to $10.55 Range Remains in Focus for the Current Session - Symmetrical Triangle - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMikgJBVV95cUxNY21qZEIxRlhyMlFibThXQmlwajVkS0RNM25yTEV3YVlCM2R4bFl2WWRPaVRWc0tCSVhtYmVVTGhhWTRma2ladXhJU2lsYmQyalZDV1pweFRCRlJzbjl3blRacThOSGRVTmVmTkdadFljelMtZ2RkUDA1N055ajBzMW53cWo2Q09WeTNxTk…

ICCC — Frequently Asked Questions

What is the current share price of ImmuCell Corporation (ICCC)?

As of 2026-09-19 21:16 PDT, ImmuCell Corporation (ICCC) trades at $9.84 on NasdaqCM. Its 52-week range is $4.56 to $11.72.

What is the market capitalisation of ICCC?

ImmuCell Corporation (ICCC) has a market capitalisation of $89.37M on NasdaqCM.

What is the P/E ratio of ICCC?

ICCC trades at a trailing price-to-earnings (P/E) ratio of 140.57. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.88.

What is the return on equity (ROE) of ICCC?

ICCC has a return on equity (ROE) of 2.57%. Its return on capital employed (ROCE) is 4.28%.

Is ICCC a good stock to buy?

This page provides a data-driven analysis of ImmuCell Corporation (ICCC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

ImmuCell Corporation ICCC PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Discipline and Rules-Based Execution in ICCC Response - Stock Traders Daily

ImmuCell Plans About $4.5M Expansion for Calf Health Products - Stock Titan

ICCC | Immucell Corp Financials - Revenue Breakdown - Quiver Quantitative

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 - tradingview.com

ImmuCell: First Defense With Better Execution (NASDAQ:ICCC) - Seeking Alpha

ImmuCell (ICCC) Shares: Moves 0.40% Lower to $10.05 in the Latest Reading; Price Levels: the $9.55 to $10.55 Range Remains in Focus for the Current Session - Symmetrical Triangle - vinanet.vn

ICCC — Frequently Asked Questions

What is the current share price of ImmuCell Corporation (ICCC)?

What is the market capitalisation of ICCC?

What is the P/E ratio of ICCC?

What is the return on equity (ROE) of ICCC?

Is ICCC a good stock to buy?

Explore More